The Power of Molecular MRD Monitoring NOW in India

HemaTrack ALL TM - Accurate, Reliable, Economical

In Acute Lymphoblastic Leukemia (ALL), Measurable Residual Disease (MRD) is the best predictor of outcome and is used to direct risk-stratified therapy. HemaTrackTM ALL is a robust, highly accurate, and economical MRD assay based on next generation sequencing (NGS) technology.

DKMS Life Science Lab India is bringing a molecular, DNA-based MRD diagnostic method for ALL patients with a maximum level of sensitivity at an affordable price to cancer hospitals in India.

Advantages

  • Highly sensitive and highly specific test for determining MRD
  • Robust and objective results; operator-independent analysis
  • Clonotype detection and quantification based on DNA

Ensuring Precision

  • Overall optimization of ALL treatment
  • Optimization/reduction of drug administration and chemotherapy intensity
  • Treatment suggestions based on the findings by experienced oncologists
  • Contamination monitoring and control using molecular identifiers (MID)


Dilution experiment demonstrates the sensitivity of HemaTrackTM ALL

In this experiment, DNA extracted from the cell line 'REH' with known clonotype identities was diluted with DNA extracted from a healthy donor (NC - negative control) to investigate the alignment of HemaTrackTM ALL to the ground truth in an artificial setting with known clonotype frequencies. In this dilution series, the clonotype frequencies measured by HemaTrackTM correlate impressively with the ground truth (expected clonotype frequency). HemaTrackTM ALL accurately quantifies clonotype frequencies up to a dilution of 8*10-5.

Indication

  • B- and T-cell acute lymphoblastic leukemia (ALL)
  • Research in the field of hematology and immune repertoire analysis

Purpose

  • Supporting diagnostic with an influence on the treatment protocol

Profile

  • IgH, IgK, TRG, TRD and TRB

Sensitivity

  • At least 10-4 (1 cancer cell in 10,000 healthy cells)

Material

  • Bone marrow


More information

Download PDF - HemaTrack ALL
(731 kb)

HemaTrackTM is currently applied

  • In clinical studies in India

Retrospective study (completed)

  • Cohort: 62 paediatric ALL patients
  • With 154 End of induction and End of consolidation samples
  • At TMC, Kolkata
  • HemaTrack ALL achieved high sensitivity and specificity, comparable to the gold standard method of molecular MRD, RQ-PCR.

Prospective studies (ongoing)

  • Cohort: approx. 70 paediatric and adult ALL patients
  • With approx. 140 End of induction and End of consolidation samples
  • At TMC, Kolkata

Multi Centre Prospective Study (from Q1 2025)

  • Extension to several hospitals across India
  • Cohort: approx. 210 paediatric ALL patients
  • With approx. 350 End of induction and End of consolidation samples

If you are interested in the results of the studies, send us your contact details via contact form.

Scope of Services

  • Electronic ordering system
  • Sample pick-up service via courier
  • Digital reporting of test results
  • Customer service for medical professionals

Contact


Dr Anindita Dutta

Head of Lab Strategy and Operations

DKMS Life Science Lab Pvt. Ltd.

info@dkms-lab.in

contact form


DKMS Life Science Lab Pvt. Ltd. India

is an subsidiary of the non-profit organization DKMS Life Science Lab in Germany.

We aim to support the DKMS in the fight against blood cancer and other diseases of the hematopoietic system. We contribute to the improvement of treatment options through the best possible patient diagnostics services to save the lives of as many patients as possible.

Partner






Contact
Dr Anindita Dutta

Head of Lab Strategy and Operations

An updated version of this page is available.